Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study

Adjuvant platinum-based chemotherapy is standard treatment for surgically resected stage II to IIIA NSCLC, but the relapse rate is high. The preferentially expressed antigen of melanoma (PRAME) tumor antigen is expressed in two-thirds of NSCLC and offers an attractive target for antigen-specific imm...

Full description

Bibliographic Details

Published in:	Journal of thoracic oncology Vol. 11; no. 12; pp. 2208 - 2217
Main Authors:	Pujol, Jean-Louis, De Pas, Tommaso, Rittmeyer, Achim, Vallières, Eric, Kubisa, Bartosz, Levchenko, Eugeny, Wiesemann, Sebastian, Masters, Gregory A, Shen, Robert, Tjulandin, Sergei A, Hofmann, Hans-Stefan, Vanhoutte, Nicolas, Salaun, Bruno, Debois, Muriel, Jarnjak, Silvija, De Sousa Alves, Pedro Miguel, Louahed, Jamila, Brichard, Vincent G, Lehmann, Frédéric F
Format:	Journal Article
Language:	English
Published:	United States 01.12.2016
Subjects:	Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy, Adjuvant - methods Female Humans Immunotherapy - methods Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Adjuvant setting PRAME antigen Safety NSCLC Immunotherapy
ISSN:	1556-1380
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!